Share this NATF page   

Compass Trial Results: Coming Soon

Results of the Phase 3 COMPASS trial are set to be released this month at the European Society of Cardiology. The trial, which was stopped early for efficacy, may have a significant impact on patients with coronary artery disease (CAD) and peripheral artery disease (PAD).

The COMPASS trial examined the use of rivaroxaban to prevent cardiovascular events, such as stroke and heart attack, in patients with CAD or PAD. CAD and PAD are both serious conditions that develop when the body’s arteries begin to narrow, making it difficult for blood to flow. This narrowing is due to a buildup of plaque along the artery walls, a condition known as atherosclerosis.

The original trial wasn’t scheduled to end until March 2018, but concluded in January 2017 because the primary endpoint was met ahead of schedule. In the trial, 27,402 patients were randomized to receive rivaroxaban at 2.5 mg twice daily, combined with aspirin at 100 mg per day, rivaroxaban at 5 mg twice a day with no aspirin, or just 100 mg of aspirin a day, with no rivaroxaban.

“The COMPASS trial results may be an advance in the management of stable coronary artery disease and stable peripheral artery disease,” remarked Dr. Deepak L. Bhatt, the Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. “Peripheral artery disease is particularly a disease state for which we don’t have many effective therapies.”

While trial results have not been released yet, they could be a major step forward for the treatment of CAD and PAD.

“There is still the ability to improve the care of patients with CAD and PAD,” he continued. “It appears that rivaroxaban at lower doses might provide added protection.”

Dr. Bhatt will delve into the widely anticipated results at NATF’s upcoming Thrombosis Summit on September 16, 2017. He will provide an exciting review of the trial’s background, including what trials inspired COMPASS, and will give his expert insight into the impact that the results carry, and how practitioners can use the new data in their clinical practice.

Register now.

About NATF





Giving to NATF

North American Thrombosis Forum
368 Boylston Street
Brookline, MA 02445

617 - 730 - 4120

NATF is a 501(c) nonprofit

Contact Us

© 2012 North American Thrombosis Forum

Web Development by MTC